Mental Health
Understanding the mental health crisis, depression, PTSD, and the importance of seeking professional help.
18 articles available
Start Here
What is Psilocybin?
Understanding the compound being researched for depression, anxiety, and PTSD treatment.
8 minSet and Setting
Creating therapeutic environments through mindset and environment preparation.
8 minWhat is Microdosing?
Sub-perceptual dosing protocols being studied for depression, anxiety, and cognitive enhancement.
9 minWhat is Ibogaine?
Research into ibogaine's potential for treating addiction and substance use disorders.
10 minMental Health & Psychedelics
Depression, PTSD, anxiety, addiction — the therapeutic research landscape.
16 minWhat is MDMA?
PTSD treatment research, empathogenic therapy, and FDA breakthrough designation.
12 minWhat is Ketamine?
Medical uses, psychiatric evidence, safety requirements, and important limitations.
14 minNavigating Psychedelic Therapy
Finding therapists, evaluating clinics, and accessing clinical trials.
14 minRelated Journal Articles
Field Notes #6: Dispatches from D.C. as Three Psychedelics Land at FDA
Field Notes are timely, candid voice notes from our Founder and Editor, Josh Hardman, that give our Pα+ readers a pulse on recent developments in psychedelic drug development, policy, and access.
Breaking: U.S. Government Taps Mark Cuban’s Company to Develop Ibogaine for PTSD; Commits to Fund $20M Real-World Evidence Network
This morning, the U.S. Department of Health and Human Services (HHS) provided an update on two psychedelics-related initiatives during a press conference hosted by its Secretary, RFK Jr.
Compass Says NDA Will Be Filed Within Two Weeks, Declines to Comment on Usona
This morning, Compass Pathways shared its Q3 2026 results, which included an update on its COMP360 psilocybin for treatment-resistant depression (TRD) new drug application (NDA) submission.
Usona Files Psilocybin for Depression NDA as Race With Compass Tightens
Nonprofit psychedelic research organisation Usona Institute has completed its submission of a new drug application (NDA) to the U.S.
Ten VA Sites, REMS and Ibogaine’s “Uphill Battle”: Feds Weigh In on Psychedelic Access
At the Psychedelic Healthcare Forum, which took place in New York City last Thursday and was co-hosted by Psychedelic Alpha, a panel of federal officials participated in a discussion moderated by POLI...
Oregon U-turns on Doubling Psilocybin License Fees
Oregon’s health regulators shelved a proposal that would have doubled what psilocybin businesses and facilitators pay for their state licenses.
How to Change Your Behavior
From How to Change Your Mind to dueling theories about the neurobiological mechanisms of psychedelics, one thing has become increasingly clear: psychedelic therapy has officially left the shadows of N...
Kenneth Tupper, PhD: Harm Reduction, Drug Education, Canadian Ayahuasca, and Psychedelic Public Health
Kenneth Tupper joins Joe Moore for a wide-ranging conversation on harm reduction, drug education, British Columbia’s toxic drug crisis, ayahuasca policy, entheogenic education, and what psychedelic pu...
2026 Third Quarter — Legislative Wrap Up
Since the beginning of 2026, at least 23 states have introduced psychedelic legislation, signaling continued momentum and openness in how local and federal leaders address mental health, substance use...
MAPS and International Alliance of Psychedelic Therapy Practitioners Announce Partnership to Advance Training for Psychedelic-Assisted Therapy
Collaboration will increase access to practitioner education in the United States and internationally.
By continuing to use this site, you agree to our Terms and Privacy Policy.

